Apyx Medical Corp
NASDAQ:APYX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.8716
4.33
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Apyx Medical Corp
Apyx Medical Corp. operates as an energy-based medical technology company. The company is headquartered in Clearwater, Florida and currently employs 272 full-time employees. The firm operates through two segments: Advanced Energy and original equipment manufacturer (OEM). Its Advanced Energy product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. These product lines consist of a multifunction generator, a handpiece, and a supply of helium gas. Its primary focus is on the cosmetic surgery market, where Renuvion offers plastic surgeons, fascial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. The firm designs, develops, and manufactures electrosurgical equipment by producing generators and related accessories for medical device manufacturers through original equipment manufacturing (OEM) agreements, as well as start-up companies with the need for its energy-based designs.
Apyx Medical Corp. operates as an energy-based medical technology company. The company is headquartered in Clearwater, Florida and currently employs 272 full-time employees. The firm operates through two segments: Advanced Energy and original equipment manufacturer (OEM). Its Advanced Energy product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. These product lines consist of a multifunction generator, a handpiece, and a supply of helium gas. Its primary focus is on the cosmetic surgery market, where Renuvion offers plastic surgeons, fascial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. The firm designs, develops, and manufactures electrosurgical equipment by producing generators and related accessories for medical device manufacturers through original equipment manufacturing (OEM) agreements, as well as start-up companies with the need for its energy-based designs.
Revenue Growth: Total revenue for Q3 2025 increased 12% to $12.9 million, driven by strong sales in the Surgical Aesthetics segment.
Surgical Aesthetics Momentum: AYON Body Contouring System launch contributed to 19% growth in the segment, with strong U.S. demand and positive market feedback.
OEM Decline: OEM revenue decreased as resources shifted to the higher-growth Surgical Aesthetics business.
Profitability Improvement: Operating expenses fell and loss from operations shrank by 77%, reflecting successful cost reductions from last year's restructuring.
Gross Margin Expansion: Gross margin improved to 64.4% from 60.5% year-on-year.
Guidance Raised: Full-year 2025 revenue guidance increased to $50.5–$52.5 million, with higher Surgical Aesthetics expectations and lower OEM projections.
Cash Position: Cash and equivalents stand at $25.1 million, with management confident in liquidity through 2027.
